175 assets in Breast Neoplasm

Therapeutic assets addressing Breast Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Metformin Breast Neoplasm	Katherine D. Crew	P2	B (56)
Trastuzumab Deruxtecan Breast Neoplasm	Merck Sharp & Dohme LLC	P3	B (56)
Utidelone Breast Neoplasm	Sun Yat-sen University	P3	B (56)
Tucatinib Breast Neoplasm	Merck Sharp & Dohme LLC	P2	CCC (55)
Dexasone Breast Neoplasm	Brown University	P2	CCC (54)
Durvalumab Breast Neoplasm	Institute of Cancer Research, United Kingdom	P2	CCC (54)
9mw2821 Breast Neoplasm	Fudan University	P2	CCC (53)
AK105 Breast Neoplasm	Liaoning Cancer Hospital & Institute	P2	CCC (53)
Anti-Pd-L1 Monoclonal Antibody Shr-1316 Breast Neoplasm	Fudan University	P2	CCC (53)
azd6738 Breast Neoplasm	Institute of Cancer Research, United Kingdom	P2	CCC (53)
Benmelstobart Breast Neoplasm	Fudan University	P2	CCC (53)
Bicalutamide Breast Neoplasm	Providence Health & Services	P2	CCC (53)
Fluzoparib Breast Neoplasm	Fudan University	P2	CCC (53)
h3b-6545 Breast Neoplasm	Eisai Co., Ltd.	P1/2	CCC (53)
hb1801 Breast Neoplasm	Fudan University	P2	CCC (53)
Hrs-4508 Breast Neoplasm	Fudan University	P2	CCC (53)
Hrs-6209 Breast Neoplasm	Fudan University	P2	CCC (53)
Hyaluronidase Zzxf Breast Neoplasm	Baylor Breast Care Center	P2	CCC (53)
ibi354 Breast Neoplasm	Fudan University	P2	CCC (53)
Immunoglobulin G1, Anti-(Human Epidermal Growth Factor Receptor Her2) (Human-Mus Musculus Monoclonal Shr-1805 ?1-Chain), Complex With Human-Mus Musculus Monoclonal Shr-1805 ?-Chain, Dimer, Thioether With N-[6-(3-Mercapto-2,5-Dioxo-1-Pyrrolidinyl)-1-Oxohexyl]Glycylglycyl-L-Phenylalanyl-N-[[(1R)-1-Cyclopropyl-2-[[(1S,9S)-9-Ethyl-5-Fluoro-2,3,9,10,13,15-Hexahydro-9-Hydroxy-4-Methyl-10,13-Dioxo-1H,12H-Benzo[De]Pyrano[3?,4?:6,7]Indolizino[1,2-B]Quinolin-1-Yl]Amino]-2-Oxoethoxy]Methyl]Glycinamide Breast Neoplasm	Fudan University	P2	CCC (53)
Ipilimumab Breast Neoplasm	Providence Health & Services	P2	CCC (53)
Ivonescimab Breast Neoplasm	Fudan University	P2	CCC (53)
js207 Breast Neoplasm	Fudan University	P2	CCC (53)
Jskn003 Breast Neoplasm	Fudan University	P2	CCC (53)
Lomustine Breast Neoplasm	Actuate Therapeutics Inc.	P2	CCC (53)
Mitoxantrone Breast Neoplasm	Fudan University	P2	CCC (53)
Shr-1167 Breast Neoplasm	Fudan University	P2	CCC (53)
Shr-4602 Breast Neoplasm	Fudan University	P2	CCC (53)
Shr-6209 Breast Neoplasm	Fudan University	P2	CCC (53)
Shr-A1921 Breast Neoplasm	Fudan University	P2	CCC (53)
Shr-A2009 Breast Neoplasm	Fudan University	P2	CCC (53)
Shr-A2102 Breast Neoplasm	Fudan University	P2	CCC (53)
Tart Cherry Breast Neoplasm	University of California, Davis	P2	CCC (53)
tqb2102 Breast Neoplasm	Fudan University	P2	CCC (53)
tqb2868 Breast Neoplasm	Fudan University	P2	CCC (53)
Trilaciclib Breast Neoplasm	wang shusen	P2	CCC (53)
Alpelisib Breast Neoplasm	Borstkanker Onderzoek Groep	P2	CCC (52)
arx788 Breast Neoplasm	Ambrx, Inc.	P2	CCC (52)
Axitinib Breast Neoplasm	Lynkcell Europe	P1/2	CCC (52)
Cediranib Breast Neoplasm	National Cancer Institute (NCI)	P2	CCC (52)
Dextrose Breast Neoplasm	Merck Sharp & Dohme LLC	P3	CCC (52)
Elacestrant Breast Neoplasm	Kristina A. Fanucci	P2	CCC (52)
Enzalutamide Breast Neoplasm	Nuvation Bio Inc.	P2	CCC (52)
hlx11 Breast Neoplasm	Shanghai Henlius Biotech	P3	CCC (52)
Ibuprofen Breast Neoplasm	Aga Khan University	P3	CCC (52)
ly4064809 Breast Neoplasm	Eli Lilly and Company	P3	CCC (52)
Pumitamig Breast Neoplasm	BioNTech SE	P3	CCC (52)
Sacituzumab Tirumotecan Breast Neoplasm	Merck Sharp & Dohme LLC	P3	CCC (52)
Trebananib Breast Neoplasm	QuantumLeap Healthcare Collaborative	P2	CCC (52)
Vepdegestrant Breast Neoplasm	Pfizer	P2	CCC (52)

Showing 51 to 100 of 175 assets

PreviousPage 2 of 4Next